124 related articles for article (PubMed ID: 1729546)
1. Phase 1 trial of oral bropirimine in superficial bladder cancer.
Sarosdy MF; Lamm DL; Williams RD; Moon TD; Flanigan RC; Crawford ED; Wilks NE; Earhart RH; Merritt JA
J Urol; 1992 Jan; 147(1):31-3. PubMed ID: 1729546
[TBL] [Abstract][Full Text] [Related]
2. Treatment of carcinoma in situ of the urinary bladder with bropirimine.
Witjes JA
Eur Urol; 1997; 31 Suppl 1():27-30. PubMed ID: 9076483
[TBL] [Abstract][Full Text] [Related]
3. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin.
Sarosdy MF; Manyak MJ; Sagalowsky AI; Belldegrun A; Benson MC; Bihrle W; Carroll PR; Ellis WJ; Hudson MA; Sharkey FE
Urology; 1998 Feb; 51(2):226-31. PubMed ID: 9495702
[TBL] [Abstract][Full Text] [Related]
4. Bropirimine, an orally active anticancer agent for superficial bladder cancer.
Akaza H; Kotake T; Machida T
Eur Urol; 1998 Aug; 34(2):107-10. PubMed ID: 9693244
[TBL] [Abstract][Full Text] [Related]
5. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.
Sarosdy MF; Lowe BA; Schellhammer PF; Lamm DL; Graham SD; Grossman HB; See WA; Peabody JO; Moon TD; Flanigan RC; Crawford ED; Morganroth J
Urology; 1996 Jul; 48(1):21-7. PubMed ID: 8693646
[TBL] [Abstract][Full Text] [Related]
6. A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():20-6. PubMed ID: 9076482
[TBL] [Abstract][Full Text] [Related]
7. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.
Sarosdy MF; Tangen CM; Weiss GR; Nestok BR; Benson MC; Schellhammer PF; Sagalowsky AI; Wood DP; Crawford ED
Urol Oncol; 2005; 23(6):386-9. PubMed ID: 16301114
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium.
Manyak MJ; Ogan K
J Endourol; 2003 Oct; 17(8):633-9. PubMed ID: 14622483
[TBL] [Abstract][Full Text] [Related]
9. [Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1997 Jan; 24(1):77-85. PubMed ID: 9020949
[TBL] [Abstract][Full Text] [Related]
10. [Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2049-53. PubMed ID: 10584570
[TBL] [Abstract][Full Text] [Related]
11. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.
Witjes WP; König M; Boeminghaus FP; Hall RR; Schulman CC; Zurlo M; Fittipaldo A; Riggi M; Debruyne FM
Eur Urol; 1999 Dec; 36(6):576-81. PubMed ID: 10559611
[TBL] [Abstract][Full Text] [Related]
12. Bropirimine in bladder cancer: clinical studies.
Sarosdy MF
Ann N Y Acad Sci; 1993 Jun; 685():301-8. PubMed ID: 8363234
[No Abstract] [Full Text] [Related]
13. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group.
Nseyo UO; Shumaker B; Klein EA; Sutherland K
J Urol; 1998 Jul; 160(1):39-44. PubMed ID: 9628601
[TBL] [Abstract][Full Text] [Related]
14. In vitro antitumor activity of bropirimine against urinary bladder tumor cells.
Tei Y; Matsuyama H; Wada T; Kurisu H; Tahara M; Naito K
Anticancer Res; 2002; 22(3):1667-71. PubMed ID: 12168852
[TBL] [Abstract][Full Text] [Related]
15. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
16. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions).
Bouffioux C; van der Meijden A; Kurth KH; Jakse G; Bono A; Hall R; Oosterlinck W; Sylvester R
Prog Clin Biol Res; 1992; 378():29-42. PubMed ID: 1301584
[No Abstract] [Full Text] [Related]
17. Current and new strategies in immunotherapy for superficial bladder cancer.
Perabo FG; Müller SC
Urology; 2004 Sep; 64(3):409-21. PubMed ID: 15351555
[No Abstract] [Full Text] [Related]
18. The effect of mitomycin C on superficial bladder cancer.
Soloway MS; Murphy WM; DeFuria MD; Crooke S; Finebaum P
J Urol; 1981 May; 125(5):646-8. PubMed ID: 6785454
[TBL] [Abstract][Full Text] [Related]
19. [Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?].
Kriegmair M; Waidelich R; Baumgartner R; Lumper W; Ehsan A; Hofstetter A
Urologe A; 1994 Jul; 33(4):276-80. PubMed ID: 7941172
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.
McKiernan JM; Holder DD; Ghandour RA; Barlow LJ; Ahn JJ; Kates M; Badalato GM; Roychoudhury A; Decastro GJ; Benson MC
J Urol; 2014 Dec; 192(6):1633-8. PubMed ID: 24996128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
